Cited 9 time in
- Title
- Current pharmacotherapies for atherosclerotic cardiovascular diseases
- Author(s)
- Jong Gil Park; G T Oh
- Bibliographic Citation
- Archives of Pharmacal Research, vol. 42, no. 3, pp. 206-223
- Publication Year
- 2019
- Abstract
- Despite the introduction of statins for lowering LDL-C level, atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death and morbidity worldwide. Combination therapies with statin and other lipid-lowering drugs, including ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, have unlocked additive benefits for treatment of ASCVD, but morbidity and mortality due to ASCVD remain high. New anti-inflammatory therapies have emerged for treatment and prevention of ASCVD to address these problems. Canakinumab neutralization of interleukin-1β (IL-1β) is the only verified therapy, and low-dose methotrexate holds promise due to its efficacy and safety for treatment of ASCVD. However, many agonistic and antagonistic candidates within inflammation pathways have failed to develop into useful drugs for ASCVD because of the complexity of the inflammatory process in atherosclerosis. In this review, we outline current and future pharmaceutical therapies for ASCVD in terms of lipid-modifying strategies and anti-inflammation treatments.
- Keyword
- Anti-inflammatory therapiesAtherosclerotic cardiovascular diseases (ASCVD)CanakinumabEzetimibeLipid-lowering drugsPCSK9 inhibitorPharmaceutical therapiesStatinMethotrexate
- ISSN
- 0253-6269
- Publisher
- Pharmaceutical Soc Korea
- DOI
- http://dx.doi.org/10.1007/s12272-019-01116-1
- Type
- Article
- Appears in Collections:
- Division of Biomedical Research > Biotherapeutics Translational Research Center > 1. Journal Articles
- Files in This Item:
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.